Antithrombotic treatment is used to reduce the risk of recurrent ischemic events in patients with acute myocardial infarction (MI). Although most patients receive dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor,
1 treatment options for those with concomitant atrial fibrillation/flutter or other indications for oral anticoagulation (OAC) include triple therapy with DAPT and OAC or dual antithrombotic treatment with a single antiplatelet agent and OAC.
2 The ischemic risk reduction conferred by these treatments comes at the expense of an increased risk of bleeding. European
2 and US
3 guidelines therefore recommend individualized antithrombotic therapy based on the patient’s ischemic and bleeding risk.
4-6 For example, the duration of DAPT can be prolonged
7,8 for patients with high ischemic risk and without high bleeding risk, and DAPT can be shortened or deescalated
9,10 for those with a high bleeding risk and lower ischemic risk.
11-13